[{"orgOrder":0,"company":"Genuine Research Center, Egypt","sponsor":"Chemipharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Genuine Research Center, Egypt","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genuine Research Center, Egypt \/ Chemipharm","highestDevelopmentStatusID":"6","companyTruncated":"Genuine Research Center, Egypt \/ Chemipharm"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Apotex Inc"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Neuraxpharm"}]

Find Clinical Drug Pipeline Developments & Deals for (+-)-Modafinil

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Acquiring the US rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil) indicated to improve wakefulness in adult patients marks a strategic milestone for Apotex.

                          Product Name : Provigil

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 09, 2025

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Sleep

                          Highest Development Status : Approved FDF

                          Sponsor : Apotex Inc

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Neuraxpharm has acquired these products Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of EDS in adults with narcolepsy.

                          Product Name : Provigil

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 07, 2025

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Sleep

                          Highest Development Status : Approved FDF

                          Sponsor : Neuraxpharm

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Genuine Research Center, Egypt

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Genuine Research Center, Egypt

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Modafinil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 11, 2023

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Chemipharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vigil is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 15, 2019

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Unity Health Toronto

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Unity Health Toronto

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase III

                          Sponsor : Ontario Ministry of Health and Long Term Care | The Canadian Biomarker Integration Network in Depression

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Modafinil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 08, 2018

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Ontario Ministry of Health and Long Term Care | The Canadian Biomarker Integration Network in Depression

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vigil is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sarcoma, Ewing.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 12, 2018

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vigil is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Genital Neoplasms, Female.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 08, 2017

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Mary Crowley Medical Research Center

                          Country arrow
                          OPRD
                          Not Confirmed

                          Mary Crowley Medical Research Center

                          Country arrow
                          OPRD
                          Not Confirmed

                          Details : Vigil is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 01, 2016

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Gradalis | AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vigil is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 24, 2015

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Vigil is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 14, 2015

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank